ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

INDV Indivior Plc

931.00
-19.00 (-2.00%)
17 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Indivior Plc LSE:INDV London Ordinary Share GB00BN4HT335 ORD USD0.50
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -19.00 -2.00% 931.00 935.00 937.50 953.50 906.50 938.00 325,897 16:35:11
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 1.09B 2M 0.0154 607.79 1.23B
Indivior Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker INDV. The last closing price for Indivior was 950p. Over the last year, Indivior shares have traded in a share price range of 555.00p to 1,770.00p.

Indivior currently has 129,575,205 shares in issue. The market capitalisation of Indivior is £1.23 billion. Indivior has a price to earnings ratio (PE ratio) of 607.79.

Indivior Share Discussion Threads

Showing 4026 to 4050 of 4800 messages
Chat Pages: Latest  168  167  166  165  164  163  162  161  160  159  158  157  Older
DateSubjectAuthorDiscuss
01/6/2022
14:04
Indivior Announces First Patient Included in Aelis Farma's Phase 2b Study Assessing the Efficacy, Safety and Tolerability of AEF0117 in Treatment-Seeking Subjects With Moderate to Severe Cannabis Use Disorder
01/06/2022 2:50pm
PR Newswire (US)

Indivior (LSE:INDV)
Intraday Stock Chart

Wednesday 1 June 2022

Click Here for more Indivior Charts.
SLOUGH, England and RICHMOND, Va., June 1, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) announces the enrollment of the first patient in the Phase 2b study of AEF0117 for the treatment of cannabis use disorder (CUD). This follows less than a year after Indivior and Aelis Farma announced a strategic collaboration that includes an exclusive option and license agreement for the global rights to AEF0117, a first-in-class synthetic Signaling Specific Inhibitor ("SSI") engineered to inhibit the cannabinoid type 1 ("CB1") receptor ("CB1-SSI").

timmy11
27/5/2022
14:03
@mwain, there are many opportunities out there. It were not on my radar until I stumbled upon it. I first got in at 140ish and exited at 220ish then back in later at a higher sp, then out then in and all because of them flaming Russians, since then I have stuck with it, the further buyback was totally unexpected on my part and I hope they can take as many shares off the market as possible. I was initially after 320 -oh look! hehe
casholaa
27/5/2022
13:06
Gutted I passed this up at 40p around the time of the Lupazor issue. Held and bottled it! Well done holders
mwainw1973
27/5/2022
13:05
I see them as a juicy take-over target. The more shares they take off the market benefits us too. I'm hoping for anything over 450 either way, 650 and my body will have a spontaneous reflex reaction. - Their timing is amazing, it's got to be more than luck.
casholaa
27/5/2022
12:36
Very good article in this week's shares magazine, details recent history and future earnings expectations. Summarises that the PER is too cheap given the high margins, future earnings and significant net cash.
thorpematt
27/5/2022
10:06
Indivior to Participate in Jefferies 2022 Healthcare Conference

Slough, UK and Richmond, VA - May 24, 2022 - Indivior PLC (LON: INDV) today announced that Mark Crossley, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will participate in the Jefferies 2022 Healthcare Conference in New York City.



Mark Crossley will present on June 8, 2022, at 8:00 AM (US ET).


The live presentation will be available on Indivior's website www.indivior.com and can also be viewed using the following webcast link: .

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses.


Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD.

Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease.

Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder.

Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide.

Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior .

waldron
19/5/2022
09:21
They timed the buyback very well. Truly astonishing.
casholaa
13/5/2022
10:11
Let's hope nobody screws things up for us. I feel over-confident now, for better or worse. Good luck all.
casholaa
11/5/2022
11:55
The train is waiting at the station waiting for all to board jump on before it moves off
jretlaw
09/5/2022
11:21
INDV are very shrewd and/or have some excellent advisors. I do wonder how low they may think the share price may go for the buyback. These people are just stellar in every respect. Respect to them!
casholaa
05/5/2022
10:05
IMO their share buyback will align with lots of US companies where share buybacks in the S&P500 are at all time highs and clearly US institutional investors like them, all of which should help their proposed US listing.Personally I have mixed views on buybacks, but wouldn't put me off investing. Their 73.5m buyback programme will enhance eps by about 9% when also taking on board their two year conditional share option awards (so about 67m net shares to be cancelled). Such an impact upon eps will obviously reduce the rating and entice more value investors to come aboard - which at present is where the shift seems to be. Biden also wants to raise US tax rates from 21% to 25% so cash flows will be hit and I guess now is the time to maximise buyback programmes.
disc0dave45
04/5/2022
18:52
As the purpose of the Program is to reduce the issued share capital of Indivior, to the extent permitted by law, all Ordinary Shares purchased under the Program will be cancelled.
waldron
04/5/2022
07:03
At 3 quid a pop they'd pay for every share, I think that they'd buy back approx 26.7m shares and there's about 700m+ of them out there. It would be of more benefit if they could accumulate them at a lower price. I can't recall what they would do with them once having bought them, last time they deleted them.
casholaa
03/5/2022
19:31
Yes of course because when the share price is over £3 per share you’d announce a buy back if you didn’t want to pay £3 😂

I’ve been looking for similar sized and growth US stocks and I’m coming up with a US value around $7.50. In my mind this has a long way to go yet. DYOR

youngers
03/5/2022
19:16
I don't think that they'd be wanting to be buying back shares at 3 quid a pop, given the amount of shares in circulation.
casholaa
03/5/2022
15:59
Indivior shareholders urged to block payout to jailed boss Shaun Thaxter

Alex Ralph

Monday May 02 2022, 12.01am BST, The Times

waldron
03/5/2022
12:46
Market always goes up & down.
casholaa
03/5/2022
11:55
good point ali

its not as though they are saving on future divi payments at present

most buybacks give temporary support to share price and make directors performance seem better

I would prefer to see money used for a SPECIAL divi and or profitable projects

Upcoming events on INDIVIOR PLC

05/05/22 | 11:00am Annual General Meeting


I WOULD BE VOTING AGAINST ANY BUYBACKS IF POSSIBLE

WOULD BE INTERESTED TO KNOW WHO REALLY GAINS FROM THIS PLOY APART FROM SCOPIA

waldron
03/5/2022
11:35
waldronor anyone else is this a good strategy
ali47fish
03/5/2022
08:49
3 May 2022

Indivior Announces Share Repurchase Program Details

Slough, UK and Richmond, VA, 3 May, 2022 - Indivior PLC (LON: INDV) today announced that, as outlined in its Q1 results on 28 April 2022, it will commence a share repurchase program of Indivior's ordinary shares (the "Ordinary Shares") for up to a maximum consideration of $100 million (the "Program").

Indivior PLC ("Indivior") announces that it has entered into a non-discretionary agreement with Stifel Nicolaus Europe Limited ("Stifel") in relation to the Program and for Stifel to carry out on-market purchases, acting as riskless principal, during the period commencing on 3 May, 2022 and ending no later than 31 March, 2023, of the Ordinary Shares and the simultaneous on-sale of such Ordinary Shares by Stifel to Indivior.

waldron
29/4/2022
15:56
[United Kingdom] INDIVIOR PLC (INDV)

313.60 GBX -5.14%

waldron
29/4/2022
15:33
A lot of UK equities are simply trading within a fairly tight range.I suspect its prop books that are driving the moves.There's no great investor appetite to put more money into equities per se.Recent purchases of material stocks have hit the buffers with cost margins contracting due inflationary pressures and its difficult to know where to turn as a result but Indivior is very much a special situation.
steeplejack
29/4/2022
10:12
Tree often gets shaken after figures which may free up a bit of company folk/insider stock plus the market may like to collect a little cheap stock to kick off the share buy back starting 3 May ! Just a view!
gregmorg
28/4/2022
17:08
Yes,I added a few this morning.A stock for the current mayhem afflicting world markets.
steeplejack
28/4/2022
13:16
webcast-- management sounded very upbeat. The share buy back programme starts 3 May i.e. kicks off next week.

Acceleration of sublocade revenue growth envisaged as Covid restrictions end etc. Obviously still very confident of Sublocade $1bn plus target.

Highlighted that Perseris revenue momentum will also step up as the qtrs' develop and company emphasised it retains its stated targets. Extremely excited/enthusiastic for the Aelis Farma cannabis LT potential. So I guess we will hear a lot more on this development pipeline. Phase 2 in Q2. Lots of statistics etc but sounded good. So overall I am quite relaxed with this one.

gregmorg
Chat Pages: Latest  168  167  166  165  164  163  162  161  160  159  158  157  Older

Your Recent History

Delayed Upgrade Clock